Salipro Biotech Secures Two Japanese Patents for Membrane Protein Technology Platform
核心洞察
Salipro Biotech (搜索) received two new Japanese patents protecting its proprietary Salipro® platform technology for stabilizing and extracting challenging membrane proteins (搜索).
The patents cover generation of Salipro® particles from crude membranes and direct extraction methods for membrane proteins (搜索), strengthening IP protection in Japan.
The technology enables drug discovery against "undruggable" membrane protein targets including GPCRs (搜索) and ion channels (搜索), with patent protection extending into the 2040s.
Salipro Biotech (搜索) AB announced the issuance of two new patents by the Japanese Patent Office, strengthening the company's intellectual property position for its proprietary membrane protein stabilization technology. The Stockholm-based biotech company focuses on unlocking "undruggable" membrane protein targets for next-generation therapeutic development.
Patent Portfolio Expansion
The newly granted patents include Japanese Patent No. 7702167, titled "Salipros from Crude Membranes," which protects the generation of Salipro® particles directly from crude membranes. The second patent, Japanese Patent No. 7695198, covers "Method of Direct Extraction and Purification of a Single-Species of a Membrane Protein," providing protection for direct extraction and purification processes.
These patents are integral to Salipro Biotech (搜索)'s core technology platform, designed to stabilize challenging membrane proteins (搜索) in their native-like environment. The technology enables discovery and development of therapeutics against high-value drug targets including GPCRs (搜索) and ion channels (搜索).
Strategic Market Position
"We are delighted to announce the granting of these two new patents in Japan," said Jens Frauenfeld, CEO of Salipro Biotech (搜索). "Japan is an important market for us, and these patents strengthen our existing collaborations with top-tier Japanese pharmaceutical companies and enhance the value of our Salipro® platform for future partnerships."
The company's intellectual property portfolio provides patent protection extending into the 2040s, according to Frauenfeld, who described this as "a testament to our commitment to innovation and our leadership in the field of membrane protein technology."
Technology Applications
Salipro Biotech (搜索)'s proprietary technologies are actively integrated into numerous discovery programs and partnerships with leading pharmaceutical companies worldwide. The company continues to expand its globally recognized IP portfolio, which underpins both internal R&D efforts and strategic collaborations.
The Salipro® platform technology addresses the challenge of working with membrane proteins (搜索), which represent a significant portion of current drug targets but are notoriously difficult to study and manipulate due to their instability outside cellular membranes. By maintaining these proteins in their native-like environment, the technology opens new possibilities for drug discovery against previously challenging targets.